Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Abstract

Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients. (Funded by Plexxikon and Roche Pharmaceuticals.)

Keywords

MedicineMelanomaInternal medicineRashOncologyCohortMaculopapular rashAdverse effectVemurafenibCancerProgressive diseaseGastroenterologyMetastatic melanomaDiseaseCancer research

MeSH Terms

AdultAgedAged80 and overAntineoplastic AgentsDose-Response RelationshipDrugDrug ResistanceDrug ResistanceNeoplasmFemaleHumansIndolesMaleMelanomaMiddle AgedMutationProto-Oncogene Proteins B-rafSulfonamidesTreatment OutcomeVemurafenibYoung Adult

Affiliated Institutions

Related Publications

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Peter Schmid , Sylvia Adams , Hope S. Rugo +15 more

Atezolizumab plus nab-paclitaxel prolonged progression-free survival among patients with metastatic triple-negative breast cancer in both the intention-to-treat population and t...

2018 New England Journal of Medicine 4116 citations

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn , Shukui Qin , Masafumi Ikeda +18 more

In patients with unresectable hepatocellular carcinoma, atezolizumab combined with bevacizumab resulted in better overall and progression-free survival outcomes than sorafenib. ...

2020 New England Journal of Medicine 6464 citations

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

James Larkin , Vanna Chiarion‐Sileni , René González +28 more

BACKGROUND Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advance...

2019 New England Journal of Medicine 3500 citations

Publication Info

Year: 2010
Type: article
Volume: 363
Issue: 9
Pages: 809-819
Citations: 3499
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

3499

OpenAlex

132

Influential

2986

CrossRef

Cite This

APA Style

                            
                                
                                    Keith T. Flaherty, 
                                
                                    Igor Puzanov, 
                                
                                    Kevin B. Kim
                                
                                et al.
                            
                            (2010). 
                            Inhibition of Mutated, Activated BRAF in Metastatic Melanoma. 
                            New England Journal of Medicine
                            , 363
                            (9)
                            , 809-819.
                            https://doi.org/10.1056/nejmoa1002011
                        

Identifiers

DOI: 10.1056/nejmoa1002011
PMID: 20818844
PMCID: PMC3724529

Data Quality

Data completeness: 86%